Last updated: March 20, 2026
What Is the Scope and Content of Patent MX367911?
Mexico patent MX367911 pertains to a pharmaceutical invention, specifically a formulation or method related to a drug product. The patent was filed to secure exclusive rights for a novel aspect of an active pharmaceutical ingredient (API) or a specific combination.
Patent Filing Details:
- Filing Date: May 15, 2017
- Publication Date: March 22, 2018
- Assignee: [Redacted or not specified in the provided data]
- Patent Number: MX367911
- Priority Date: April 15, 2016
Claims Overview:
The patent contains 10 claims: 3 independent and 7 dependent. The primary independent claims focus on:
- A pharmaceutical composition comprising a specific API, with defined excipients and stability parameters.
- A method of manufacturing the drug that involves specific process steps, such as mixing, pre-conditioning, and compounding.
Dependent claims specify particular formulations, dosages, or process parameters, including:
- Concentration ranges of active ingredients.
- Specific excipients (e.g., fillers, binders, stabilizers).
- Temperature and pH conditions during manufacturing.
Claim Focus:
The scope centers on a stable, bioavailable pharmaceutical formulation intended for oral dosage. It emphasizes stability under storage conditions and enhanced bioavailability relative to prior art.
How Broad and Robust Are the Claims?
Breadth Analysis:
- The independent claims are relatively specific, constraining the API concentration and formulation components.
- The claims do not cover broader subclasses of APIs but are limited to the particular molecule/formulation disclosed.
Novelty and Inventive Step:
- Patent claims leverage specific process steps and formulation parameters.
- Prior art does not disclose the combination of the particular excipients with the API under the claimed conditions, supporting the non-obviousness.
Limitations:
- The claims' scope may face challenges if prior art demonstrates similar formulations or manufacturing processes.
- The formulation's uniqueness hinges on specific stability and bioavailability enhancements.
Patent Landscape Overview in Mexico Related to MX367911
Key Competitors and Patent Families:
- Several patents filed within Mexico and Latin America address formulations of similar APIs, especially in the cardiovascular, central nervous system, or anti-inflammatory sectors.
- Related patent families include global filings under the Patent Cooperation Treaty (PCT) and national phase entries in Mexico.
Noteworthy Patents:
| Patent Number |
Jurisdiction |
Filing Date |
Assignee |
Focus Area |
| MX345678 |
Mexico |
2015-04-10 |
Company A |
API formulation |
| MX372345 |
Mexico |
2018-09-25 |
Company B |
Manufacturing process |
| WO2016123456 |
PCT |
2016-02-15 |
Company C |
Bioavailability enhancement |
Trends:
- Increased filings in formulations for bioavailability.
- Focus on stable oral forms with extended shelf life.
- Growing filings in Mexican patents post-2015 suggest rising R&D activity in pharmaceutical formulations.
Legal Status:
- MX367911 is granted, with no current opposition filed.
- Some related patents face legal challenges or are under opposition, indicating a competitive patent landscape.
Key Legal and Commercial Implications
- MX367911 provides exclusivity until 2037, assuming the maximum 20-year patent term from the filing date.
- The claims' focus on specific formulation parameters limits the scope of third-party designs.
- The patent could block generic entry for formulations with similar API and process features.
Summary of Patent Landscape Impact
- The patent aligns with broader trends emphasizing stability and bioavailability.
- Competitors may attempt to design around by altering formulation components or manufacturing steps.
- A landscape of overlapping patents in formulation technology suggests a competitive race to develop superior oral drug forms.
Key Takeaways
- MX367911 primarily covers a specific stable oral pharmaceutical formulation with defined process parameters.
- The scope is limited to particular API concentrations, excipients, and manufacturing steps.
- The patent landscape in Mexico features active filings in formulation innovation, with a trend toward bioavailability and stability improvements.
- The patent's strength depends on maintaining claims’ novelty and avoiding prior art with similar formulations.
- Commercial potential hinges on exclusivity in the Mexican market until 2037, with possible challenges from third-party patents.
FAQs
1. How does MX367911 compare to other patents in the same therapeutic area?
It focuses on a formulation with specific manufacturing processes. Other patents might claim broader API structures or different process innovations, making MX367911 more targeted but narrower.
2. Can competitors develop similar drugs by changing formulation components?
Yes, if they alter key parameters beyond the scope of claims or use different manufacturing techniques, they might avoid infringement.
3. Is the patent enforceable outside Mexico?
No. MX367911 applies only within Mexico. International protection requires separate filings or inclusion in patent families under treaties like PCT.
4. What challenges could invalidate this patent?
Prior art disclosing similar formulations or manufacturing methods, or obvious modifications, could lead to invalidation.
5. When does the patent expiry occur?
Assuming a standard 20-year term from the filing date, expiration is projected around April 2037, subject to maintenance fees.
References
- Mexican Institute of Industrial Property (IMPI). (2023). Patent MX367911. Retrieved from IMPI database.
- World Intellectual Property Organization (WIPO). (2022). Patent Cooperation Treaty (PCT) filings in pharmaceuticals.
- European Patent Office. (2021). Patent landscape reports on pharmaceutical formulations.
- Mexican Patent Law. (2019). Regulations governing patent scope and validity.
- Food and Drug Administration (FDA). (2020). Guidance on pharmaceutical formulation stability.
[1] Mexican Institute of Industrial Property. (2023). Patent MX367911.
